Search Result

Results for "

CSF-1R Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	c-Fms (57) Apoptosis (5) Aurora Kinase (1) Autophagy (1) Bcr-Abl (1) c-Kit (9) Discoidin Domain Receptor (1) ERK (1) FGFR (5) FLT3 (2) MEK (1) PDGFR (7) Raf (2) Ras (1) TAM Receptor (2) Tie (1) VEGFR (8)
By Research Areas:	Cancer (47) Cardiovascular Disease (2) Inflammation/Immunology (14) Neurological Disease (11)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Targets Recommended: c-Fms

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-162309

CSF1R-IN-20	c-Fms	Cancer
CSF1R-IN-20 (compound 7a) is a *CSF-1R* Inhibitor with an IC₅₀ value of 467 nM. CSF1R-IN-20 inhibits CSF-1R auto-phosphorylation .

HY-159503A

Segigratinib hydrochloride 3D185; HH185	FGFR c-Fms	Cancer
Segigratinib hydrochloride (3D185) is a potent inhibitor of FGFR1/2/3 and *CSF-1R; The IC₅₀* values for FGFR1, FGFR2, FGFR3 and CSF-1R are 0.5, 1.3, 3.6 and 3.8 nM, respectively. Segigratinib hydrochloride has antitumor activity .

HY-157996

CSF1R-IN-21	c-Fms	Neurological Disease
CSF1R-IN-21 (compound 7e) is a *CSF-1R* Inhibitor with an IC₅₀ value of 31 nM. CSF1R-IN-21 inhibits *CSF-1R* auto-phosphorylation and can be used for the research of neurodegenerative diseases .

HY-147608

CSF1R-IN-7	c-Fms	Neurological Disease
CSF1R-IN-7 (Formula I) is a *CSF-1R* inhibitor. CSF1R-IN-7 can be used for Alzheimer’s disease research .

HY-147611

CSF1R-IN-10	c-Fms	Cancer
CSF1R-IN-10 (Compound 48) is a *CSF-1R* inhibitor with an IC₅₀ of 0.005 μM .

HY-147609

CSF1R-IN-8	c-Fms	Cancer
CSF1R-IN-8 (Compound 22) is a *CSF-1R* inhibitor with an IC₅₀ of 0.012 μM .

HY-147610

CSF1R-IN-9	c-Fms	Cancer
CSF1R-IN-9 (Compound 46) is a *CSF-1R* inhibitor with an IC₅₀ of 0.028 μM .

HY-144040

CSF1R-IN-4	c-Fms	Cancer
CSF1R-IN-4 is a potent inhibitor of *CSF1R. CSF-1R* is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-4 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-4 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 104) .

HY-144041

CSF1R-IN-5	c-Fms	Cancer
CSF1R-IN-5 is a potent inhibitor of *CSF1R. CSF-1R* is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-5 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-5 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 11) .

HY-144042

CSF1R-IN-6	c-Fms	Cancer
CSF1R-IN-6 is a potent inhibitor of *CSF1R. CSF-1R* is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-6 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-6 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 5) .

HY-101774

CSF1R-IN-1 1 Publications Verification	c-Fms	Cancer
CSF1R-IN-1 is a *CSF1R* inhibitor with an with an IC₅₀ of 0.5 nM.

HY-157422

CSF1R-IN-19	c-Fms	Cancer
CSF1R-IN-19 is a potent inhibitor of *CSF1R. CSF1R-IN-19 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R*-IN-19 has the potential for the research of cancer .

HY-160842

CSF1R-IN-24	c-Fms	Neurological Disease
CSF1R-IN-24 (Example 134) is an orally active *CSF1R* inhibitor. CSF1R-IN-24 significantly inhibits the survival of human ipSC-derived microglia (hiPSC-MG) .

HY-158363

CSF1R-IN-25	c-Fms	Neurological Disease Inflammation/Immunology Cancer
CSF1R-IN-25 (compound 36) is an orally effective *CSF1R* inhibitor. CSF1R-IN-25 can be used to study cancer, inflammation, and neurodegeneration .

HY-155550

CSF1R-IN-17	c-Fms	Inflammation/Immunology
CSF1R-IN-17 (compound 9) is a potent and selective *CSF1R* antagonist, with an IC₅₀ of 0.2 nM. CSF1R-IN-17 can inhibit osteoclast differentiation .

HY-153277

Axl/Mer/CSF1R-IN-2	TAM Receptor c-Fms	Neurological Disease
Axl/Mer/CSF1R-IN-2 (Comp 4) is a Axl, Mer and *CSF1R* inhibitor .

HY-P99245

Emactuzumab RG 7155; RO 5509554	c-Fms	Cancer
Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor *(CSF1R)* activation. Emactuzumab has high affinity for CSF-1R with K_i value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .

HY-158148

CSF1R-IN-23	c-Fms	Neurological Disease Inflammation/Immunology
CSF1R-IN-23 (Compound 7dri) is a selective inhibitor for colony-stimulating factor-1 receptor (CSF1R), with IC₅₀ of 36.1 nM. CSF1R-IN-23 serves as antineuroinflammatory agent in mouse model. CSF1R-IN-23 is blood brain barrier (BBB) permeable .

HY-117244

AZD7507 1 Publications Verification	c-Fms	Cancer
AZD7507 is a potent and orally active *CSF-1R* inhibitor, with antitumor activity.

HY-139990

CSF1R-IN-3	c-Fms	Cancer
CSF1R-IN-3 (compound 21) is a potent and orally active *CSF-1R* inhibitor (IC₅₀=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity .

HY-155001

CSF1R-IN-15	c-Fms	Others
CSF1R-IN-15 (compound 23) is an inhibitor targeting *CSF1R. The colony-stimulating factor-1 receptor (CSF1R) is a tyrosine kinase embedded in the cell membrane of macrophages. The receptor is activated by colony-stimulating factor-1 (CSF-1) and interleukin-34, and signaling via CSF1R* is crucial for the differentiation, proliferation, and survival of macrophages .

HY-161084

CSF1R-IN-18	c-Fms	Neurological Disease Cancer
CSF1R-IN-18 (Compdound 16t), para-aniline derivative, is a colony-stimulating factor 1 receptor (CSF1R) inhibitor. CSF1R-IN-18 can be used for the research of cancers, CNS-diseases and bone diseases .

HY-153920

Pimicotinib ABSK021	c-Fms	Cancer
Pimicotinib is a CSF1R inhibitor with antitumor activity .

HY-162415

CSF1R-IN-22	c-Fms Apoptosis	Cancer
CSF1R-IN-22 (Compound C19) is an orally effective *CSF-1R* selective inhibitor (IC₅₀<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8 ⁺ T cell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8 ⁺ T cells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs .

HY-147617

CSF1R-IN-14	c-Fms	Cancer
CSF1R-IN-14 is an isoindolinone derivative compound. CSF1R-IN-14 is a potent inhibitor of *CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R*-IN-14 has the potential for the research of cancer diseases (extracted from patent WO2019134662A1, compound 1) .

HY-101526

GENZ-882706 RA03546849	c-Fms	Inflammation/Immunology
GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1.

HY-122906

JTE-952	c-Fms	Inflammation/Immunology
JTE-952 is a potent, oral active and selective Type II inhibitor of colony stimulating factor-1 receptor (CSF-1R or cFMS, type III receptor tyrosine kinase), with IC₅₀ values of 13 nM and 261 nM for CSF1R and TrkA , respectively. Effective against a mouse collagen-induced model of arthritis .

HY-147615

CSF1R-IN-12	c-Fms	Cancer
CSF1R-IN-12 is a potent inhibitor of *CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R*-IN-12 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 1) .

HY-147616

CSF1R-IN-13	c-Fms	Cancer
CSF1R-IN-13 is a potent inhibitor of *CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R*-IN-13 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 32) .

HY-159108

AZ683	c-Fms	Cardiovascular Disease
AZ683 is a potent and selective 3-amido-4-anilinoquinoline *CSF1R* inhibitor. AZ683 has high affinity for *CSF1R* (K_i=8 nM; IC₅₀=6 nM). AZ683 has good oral bioavailability. [ ¹¹C]AZ683 can be used as a positron emission tomography (PET) radiotracer for colony stimulating factor 1 receptor (CSF1R) .

HY-119942

c-Fms-IN-8	c-Fms	Cancer
c-Fms-IN-8 (compound 4a) is a *colony stimulating factor-1 receptor (CSF-1R, c-FMS)* Type II inhibitor, with an IC₅₀ of 9.1 nM .

HY-112451

cFMS Receptor Inhibitor II	c-Fms	Inflammation/Immunology
cFMS Receptor Inhibitor II is a *CSF1R* kinase inhibitor. CSF-1 is a cytokine .

HY-101768

PRN1371 1 Publications Verification	FGFR c-Fms	Cancer
PRN1371 is a highly selective and potent FGFR1-4 and *CSF1R* inhibitor with IC₅₀s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively .

HY-132935

BPR1R024	c-Fms	Inflammation/Immunology Cancer
BPR1R024 is an orally active and selective colony-stimulating factor-1 receptor (CSF1R) inhibitor. BPR1R024 has potent CSF1R inhibition activity with an IC₅₀ value of 0.53 nM. BPR1R024 can be used for the research of immuno-oncology .

HY-161025

SYHA1813	c-Fms VEGFR	Cancer
SYHA1813 is a dual inhibitor of CSF1R and VEGFR. SYHA1813 has potent antitumor activity against GBM .

HY-12768

Sotuletinib 15+ Cited Publications BLZ945	c-Fms	Cancer
Sotuletinib (BLZ945) is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC₅₀ of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs .

HY-12768A

Sotuletinib hydrochloride 15+ Cited Publications BLZ945 hydrochloride	c-Fms	Cancer
Sotuletinib (BLZ945) hydrochloride is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC₅₀ of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs .

HY-126297

c-Fms-IN-10	c-Fms	Inflammation/Immunology Cancer
c-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, an kinase inhibitor of FMS (Colony stimulating factor-1 receptor, CSF-1R) with IC₅₀ of 2 nM. c-Fms-IN-10 has anti-tumor activity .

HY-16749A

Pexidartinib hydrochloride Maximum Cited Publications 80 Publications Verification PLX-3397 hydrochloride	c-Fms c-Kit Apoptosis	Cancer
Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive *colony stimulating factor 1 receptor (CSF1R* or M-CSFR) and c-Kit** inhibitor, with IC₅₀s of 20 and 10 nM, respectively. Pexidartinib hydrochloride exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib hydrochloride induces cell apoptosis and has anti-cancer activity .

HY-132935A

BPR1R024 mesylate	c-Fms	Inflammation/Immunology Cancer
BPR1R024 mesylate is an orally active and selective colony-stimulating factor-1 receptor (CSF1R) inhibitor. BPR1R024 mesylate is the equivalent of BPR1R024 (HY-132935). BPR1R024 has potent CSF1R inhibition activity with an IC₅₀ value of 0.53 nM. BPR1R024 can be used for the research of immuno-oncology .

HY-153243

IACS-9439	c-Fms	Cancer
IACS-9439 is a potent, selective, and orally active *CSF1R* inhibitor with a K_i value of 1 nM inhibitor. IACS-9439 can be used for advanced solid tumors research .

HY-10408

Ki20227 5 Publications Verification	c-Fms VEGFR c-Kit PDGFR	Inflammation/Immunology
Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC₅₀s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction .

HY-153012

Axl/Mer/CSF1R-IN-1	TAM Receptor c-Fms	Cancer
Axl/Mer-IN-1 (Compound 1) is an Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and *CSF1R* inhibitor with K_ds of <0.1 μM .

HY-16749

Pexidartinib Maximum Cited Publications 80 Publications Verification PLX-3397	c-Fms c-Kit Apoptosis	Cancer
Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive *colony stimulating factor 1 receptor (CSF1R* or M-CSFR) and c-Kit** inhibitor, with IC₅₀s of 20 and 10 nM, respectively. Pexidartinib (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib (PLX-3397) induces cell apoptosis and has anti-tumor activity .

HY-12297

Sulfatinib 2 Publications Verification Surufatinib; HMPL-012	FGFR VEGFR	Cancer
Sulfatinib (Surufatinib) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and *CSF1R* with IC₅₀s of in a range of 1 to 24 nM.

HY-13493

AC710	PDGFR c-Kit FLT3	Cancer
AC710 is a potent PDGFR inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.

HY-13493A

AC710 Mesylate	PDGFR	Cancer
AC710 Mesylate is a potent PDGFR inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.

HY-136362

ARRY-382	c-Fms	Inflammation/Immunology Cancer
ARRY-382 is a potent, oral and highly selective inhibitor of *CSF1R/c-Fms* with an IC₅₀ of 9 nM. ARRY-382 can be used for the research of advanced or metastatic cancers .

HY-10204

OSI-930 4 Publications Verification	c-Kit VEGFR c-Fms Apoptosis	Cancer
OSI-930 is an orally selective inhibitor of Kit, KDR and CSF-1R (c-Fms) with IC₅₀s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, c-Raf, Lck and low activity against PDGFRα/β, Flt-3 and Abl. OSI-930 has antitumor activity .

HY-124526

Chiauranib Ibcasertib; CS2164	VEGFR PDGFR c-Kit Aurora Kinase c-Fms	Cancer
Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase *CSF-1R, with IC₅₀* values ranging from 1-9 nM. Chiauranib has strongly anticancer effects .

Cat. No.	Product Name	Target	Research Area

HY-P99245

Emactuzumab RG 7155; RO 5509554	c-Fms	Cancer
Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor *(CSF1R)* activation. Emactuzumab has high affinity for CSF-1R with K_i value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .

HY-P990125

Anti-Mouse (CSF1R/CD115) Antibody (AFS98)	Inhibitory Antibodies	Others
Anti-Mouse CSF1R (CD115) Antibody (AFS98) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CSF1R.

HY-P99259

Cabiralizumab FPA 008; Anti-Human CSF1R Recombinant Antibody	c-Fms	Inflammation/Immunology Cancer
Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P99245

Emactuzumab RG 7155; RO 5509554	Classification of Application Fields Disease Research Fields Cancer	c-Fms
Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor *(CSF1R)* activation. Emactuzumab has high affinity for CSF-1R with K_i value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .

HY-P99259

Cabiralizumab FPA 008; Anti-Human CSF1R Recombinant Antibody	Classification of Application Fields Disease Research Fields Cancer	c-Fms
Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CSF-1R Inhibitor

Inhibitors & Agonists

Inhibitory Antibodies

NaturalProducts

Natural
Products